All > Breast Cancer Hawaii > Breast

ZetaFuse™ Bone Graft for Metastatic Breast Cancer in the Spine

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Metastatic Breast Cancer in the SpineZetaFuse™ Bone Graft - Device
Eligibility
22 - 75
Female
What conditions do you have?
Select

Study Summary

This trial is for patients with cancer that has spread to up to 5 areas, who have a spinal instability score of 3-9, who are having the ZetaFuse bone graft implanted in their spine to help with the tumor.

Eligible Conditions
  • Metastatic Breast Cancer in the Spine

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Standard of care (SOC) dressings
1
XenMatrix™ AB Surgical Graft
1
surgical transplantation of CECA

Study Objectives

8 Primary · 0 Secondary · Reporting Duration: 6 months

6 months
Average daily dose of postoperative prescription opioid use.
Change in Back-specific Numeric Rating Scale for Pain (Back NRS) compared to baseline.
Change in SINS assessment compared to baseline.
Change in vertebral body defect size at 42- and 180-day follow-up visits compared to baseline.
Device Feasibility and Preliminary Effectiveness as measured In Number of Skeletal Related Events (SRE) by 180-day follow-up visit.
Opioids
Safety Evaluation
Short Form 12v2 (SF-12v2) at 180-day follow-up visits compared to baseline

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Standard of care (SOC) dressings
1
XenMatrix™ AB Surgical Graft
1
surgical transplantation of CECA

Trial Design

1 Treatment Group

Investigational Device The ZetaFuse™ Bone Graft
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: ZetaFuse™ Bone Graft · No Placebo Group · N/A

Investigational Device The ZetaFuse™ Bone Graft
Device
Experimental Group · 1 Intervention: ZetaFuse™ Bone Graft · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

Zetagen Therapeutics, IncLead Sponsor

Eligibility Criteria

Age 22 - 75 · Female Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are between 22 and 75 years old.
You have 5 or fewer metastases located at 3 or fewer sites.
A lytic metastatic lesion located in the vertebral body of the spine.
You have a normal spine.\n
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top